Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Innovative-Molecules

More Like This

PR Newswire associated0

Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir

PR Newswire associated0

Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

PR Newswire associated0

IRBM Reports Breakthrough in Zika Virus Drug Discovery

Biotech company Eradivir is developing lead drug EV25 to treat influenza

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome